The biomanufacturing industry has now the opportunity to upgrade its production processes to be in harmony with the latest industrial revolution. Technology creates capabilities that enable smart manufacturing while still complying with unfolding regulations. However, many biomanufacturing companies, especially in the biopharma sector, still have a long way to go to fully benefit from smart manufacturing as they first need to transition their current operations to an information-driven future. One of the most significant obstacles towards the implementation of smart biomanufacturing is the collection of large sets of relevant data. Therefore, in this work, we both summarize the advances that have been made to date with regards to the monitoring and control of bioprocesses, and highlight some of the key technologies that have the potential to contribute to gathering big data. Empowering the current biomanufacturing industry to transition to Industry 4.0 operations allows for improved productivity through information-driven automation, not only by developing infrastructure, but also by introducing more advanced monitoring and control strategies.

Continuous manufacturing of biologics (biopharmaceuticals) has been an area of active research and development for many reasons, ranging from the demand for operational streamlining to the requirement of achieving obvious economic benefits. At the same time, biopharma strives to develop systems and concepts that can operate at similar scales for clinical and commercial production—using flexible infrastructures, such as single-use flow paths and small surge vessels. These developments should simplify technology transfer, reduce footprint and capital investment, and will allow to react readily to changing market pressures while maintaining quality attributes. Despite a number of clearly identified benefits compared to traditional batch processes, continuous bioprocessing is still not widely adopted for commercial manufacturing. This paper details how industry-specific technological, organizational, economic, and regulatory barriers that exist in biopharmaceutical manufacturing are hindering the adoption of continuous production processes. Based on this understanding, the roles of process systems engineering (PSE), process analytical technologies, and process modeling and simulation are highlighted as key enabling tools in overcoming these multi-faceted barriers in today’s manufacturing environment. Of course, we do recognize that there is also a need for a clear set of regulations to guide a transition of biologics manufacturing towards continuous processing. Furthermore, the role played by the emerging fields of process integration and automation as well as digitalization is explored, as these are the tools of the future to facilitate this transition from batch to continuous production. Finally, an outlook focusing on technology, management, and regulatory aspects is presented to identify key concerted efforts required to drive the broad adaptation of continuous manufacturing in biopharmaceutical processes.

Modeling is a crucial tool in the biomanufacturing industry, namely in fermentation processes. This work discusses both mechanistic and data-driven models, each with unique benefits and application potential. It discusses semi-parametric hybrid modeling, a growing field that combines these two types of models for more accurate and easy result extrapolation. The characteristics and structure of such hybrid models will be examined. Moreover, its versatility will be highlighted, showing its usefulness in various stages of process development, including real-time monitoring and optimization. Scale-up remains one of the most relevant topics in fermentation processes, as it is important to have reproducible critical quality attributes, such as titer and yield, on larger scales. Furthermore, the process still relies on empirical correlations and iterative optimization. For these reasons, it is important to improve scale-up predictions, through e.g., the use of digital tools. Perspectives will be presented on the potential that hybrid modeling has by predicting performance across different process scales. This could provide more efficient and reliable biomanufacturing processes that require less resource consumption through experimentation.

This work investigates the potential of hybrid modelling in the digitalization of the chemical and biochemical industries. Hybrid modelling combines first-principles with data-driven models and is a vital enabler for the knowledge-informed transition to Industry 4.0 and, ultimately, 5.0. By integrating data with mechanistic know-how, hybrid modelling facilitates the implementation of “smart manufacturing”. Although there have been many innovations in the field of machine learning, AI, and cloud computing, the industry is still some distance away from becoming truly digital; this is particularly true in the case of the biochemical industry, which in many ways still is in the industry 3.0 stages. This gap hinders the full realization and benefits of the digital transition, such as easier process optimization, better cost-efficiency balance, and overall improved competitiveness and sustainability. This research delves into documented examples of hybrid modeling in chemical and biochemical engineering research and industries. It aims to illustrate current motivations, implementation challenges, and practical issues that hybrid modeling can address. The goal is to derive the path towards fully implementing hybrid modeling as an effective tool and key enabler for creating true digital twins and successful digitalization.